ABI
BIB icon

Adamant Biomedical Investments’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Adamant Biomedical Investments’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$1.88M Sell
30,000
-70,000
-70% -$4.11M 0.45% 66
2014
Q3 		$5.2M Buy
+100,000
New +$4.85M 1.3% 25

Other funds holding BIB

AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Adamant Biomedical Investments's BIB Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its ProShares Ultra NASDAQ Biotechnology (BIB) stake by 70% in Q4 2014, selling an estimated $4.11M and leaving 30,000 shares worth $1.88M. The position accounts for 0.45% of the portfolio, ranked #66.

Adamant Biomedical Investments first reported a position in BIB in Q3 2014 and has held it in 2 quarters since. The position peaked at $5.2M in Q3 2014. 29 funds tracked by Wall St. Rank hold BIB as of Q4 2014.

  • Adamant Biomedical Investments held 30,000 shares of ProShares Ultra NASDAQ Biotechnology worth $1.88M as of Q4 2014.
  • Adamant Biomedical Investments sold 70,000 ProShares Ultra NASDAQ Biotechnology shares in Q4 2014, an estimated $4.11M.
  • ProShares Ultra NASDAQ Biotechnology made up 0.45% of Adamant Biomedical Investments's portfolio in Q4 2014, its #66 holding.
  • Adamant Biomedical Investments first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's ProShares Ultra NASDAQ Biotechnology position peaked at $5.2M in Q3 2014.
  • 29 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.